Ravichandran, Vignesh
Shameer, Zarina
Kemel, Yelena
Walsh, Michael
Cadoo, Karen
Lipkin, Steven
Mandelker, Diana
Zhang, Liying
Stadler, Zsofia
Robson, Mark
Offit, Kenneth
Vijai, Joseph http://orcid.org/0000-0002-7933-151X
Text and Data Mining valid from 2019-02-21
Article History
Received: 21 August 2018
Accepted: 6 February 2019
First Online: 21 February 2019
Change Date: 21 March 2019
Change Type: Update
Change Details: An update to the original published conflict of interest for author Liying Zhang, PhD. L.Z. received compensation from Future Technology Research LLC (seminar on precision medicine), Roche Diagnostics Asia Pacific, BGI, Illumina (speaking activities at conferences/workshop). L.Z.'s family member has a leadership position and ownership interest of Shanghai Genome Center. This correction has been made.
Disclosure
: L.Z. received compensation from Future Technology Research LLC (seminar on precision medicine), Roche Diagnostics Asia Pacific, BGI, Illumina (speaking activities at conferences/workshop). L.Z.'s family member has a leadership position and ownership interest of Shanghai Genome Center. Y.K. was a past employee of Bioreference Laboratories, a subsidiary of OPKO Health, with employment ending in January 2016. K.C. declares institutional support for therapeutic clinical trial from AstraZeneca and Syndax Pharmaceuticals outside the submitted work. Z.S. declares her immediate family member works at the department of Ophthalmology at MSKCC. She also holds consulting/advisory roles with Allergan, Adverum Biotechnologies, Alimera Sciences, Biomarin, Fortress Biotech, Genentech, Novartis, Optos, Regeneron, Regenxbio, Spark Therapeutics. M.R. declares grants, personal fees and nonfinancial support from AstraZeneca, personal fees from McKesson, grants and personal fees from Pfizer, nonfinancial support from Myriad, nonfinancial support from Invitae, grants from AbbVie, grants from Tesar, grants from Medivation outside the submitted work. V.J. and K.O. declare that they hold patent on the “Diagnosis and Treatment of ERCC3 mutant cancer” PCT/US18/22588. The other authors declare no conflicts of interest.